| ObjectivePancreatic cancer is a relatively little malignant tumor in the digestive system. But, in recent years, the incidence of disease has the trend of evident increase. Pancreatic cancer's ageadjusted mortality amount to 9/10 ten thousand population in 1970 from 2. 9/10 ten thousand population in 1920. About 24500 peoples die for Pancreatic cancer ( THE CANCER ASSOCIATION OF THE U-NITED STATES, 1988). The incidence of disease of Pancreatic cancer has an ascended tendency. The rate of excision has also been advanced. However, The rate of survival is still on 5% or so. Therefore, in the instance of the methods of Pancreatic cancer' s morning diagnose have not been break through. For the intermediate stage and advanced stage patients of Pancreatic cancer, how to apply with reasonable combined therapy so as to boost the patients life span and improve the quality of life is the problem that the clinical surgery at the present stage should pay close attention to.Telomeres form the ends of eucaryon filate chromosomes composed of te-lomere deoxyribonucleic acid and telomere binding protein consisting of an array of repeated sequence of conservative 5'- TTAGGG - 3' From 5'- 3',length 5 -15kb. The length of telomeres need the activated telomerase to retain. The activated telomerase takes the 3' distal end of telomeres as the primer and its UNA component acts as the template. Human telomerase is a ribonucleoprotein complex, composed of a catalytic reverse transcriptase subunit (hTERT) , an RNA component ( hTR) that serves as a template for the synthesis of telomeric repeats , and an associated protein subunit (TP1). Several researchers have re-ported high levels of hTERT expression in malignant tissues but not in non - malignant tissues. There is a close correlation between hTERT and telomerase activity. Telomerase plays an important role in the development of cellular immortality and oncogenesis.Because telomerase has a close correlation with malignant tumor. The activity of telomerase will prominent depress, after tumour cell be killed and wounded by chemotherapy and then differentiation . the mechanism still need to be illuminated. But, It cued us that the medicine aimed directly at the activity of telomerase might provide a new way to cure the tumor. So the inhibitors of telomerase were thought a quite potential anti - tumor factor, telomerase is the latest and special target. The gene therapy by means of refraining the activity of telomerase, Passing through make the activity of telomerase loss so as to inhibit the tumor cell growth, might become the effective way to cure the malignant tumor. In this study, we apply antisense Oligonucleotide aimed directly at catalytic reverse transcriptase subunit ( hTERT). To research the influence of antisense Oligonucleotide effect the activity of telomerase of Pancreatic Cancer Bxpc - 3 cell and investigate the potential value of telomerase hTERT gene as a target for anti-sense gene therapy in pancreatic cancer.MethodMTT assay was used to detect the effect of hTERT - ASO on proliferation of Bxpc - 3 cell in the different dose and for different time. There were three groups for anti - tumor activity study. The Pancreatic Cancer Bxpc -3 cell control group, antisense Oligonucleotide(hTERT - ASO)group and sense Oligpnu-cleotide group decorated with Phosphorothioate. Telomerase activity was detected by TRAP - PCR - ELISA. Cell DNA distribution were studied by flow cy-tometer.Statistical analysisResults were expressed as the means SD. Statistical analyses were carried out with the software package SPSS10.0. Compare the means among the groups with analysis of variance of repeated measures. P <0.05 was considered statisti-cal significance.ResultsGrowth arrest of human Bxpc - 3 Pancreatic Cancer Cell . 24,48,72,96 hours after incubation with the cell, S - ODN and Pancreatic Cancer Bxpc -3 cell control group have not the discrepancy ( F =0.013 ,P >0. 05) , It demonstrate that S - ODN has no effect on cell normal growth compared with Pancreatic Ca... |
PDF Full Text Request